Background/Aims Venous thromboembolism (VTE) is the most common complication after major joint surgery. VTE can easily develop into pulmonary embolism (PE), leading to cardiopulmonary dysfunction or sudden death. We aimed to comprehensively analyse the thromboprophylactic drugs that are used to prevent thrombosis and reduce bleeding risk. Methods: We searched the PubMed, EMBASE, and Cochrane databases for randomized controlled trials that evaluated the use of thromboprophylaxis after major joint surgery. The major outcomes were the numbers of all-cause VTE and bleeding events, and the secondary outcomes were major VTE and major bleeding/clinically relevant non-major bleeding events. A random-effects network meta-analysis was used to assess the effectiveness and tolerability of each anticoagulant after major joint surgery. Results: We included 104 trials that assessed 110,643 patients in our meta-analysis. The cluster ranking of major outcomes indicated that FXI-ASO, ardeparin, aspirin, and apixaban were ideal for preventing all-cause VTE and avoiding all bleeding events. Nadroparin, recombinant hirudin, and rivaroxaban effectively inhibited VTE but were associated with a high risk of bleeding. For secondary outcomes, we found that betrixaban, dalteparin, warfarin, and eribaxaban were ideal for preventing major VTE and reducing major bleeding, while rivaroxaban effectively inhibited major VTE but was associated with a high risk of major/clinically relevant non-major bleeding. A sensitivity analysis showed that the effect of apixaban was more robust for major outcomes, while aspirin was more robust for preventing all-cause bleeding events. In secondary outcomes, the effect of warfarin was more robust, while apixaban was still considered an ideal treatment to inhibit major VTE and bleeding events. Conclusion: Our study indicates that FXI-ASO, ardeparin, aspirin, and apixaban are ideal for preventing all-cause VTE and reducing all bleeding events, among which apixaban is the most reliable. Betrixaban, dalteparin, warfarin, and eribaxaban are ideal for preventing major VTE and reducing major/clinically relevant non-major bleeding events, among which warfarin is the most reliable.
"thromboprophylaxis", "knee arthroplasty", "hip arthroplasty", "knee replacement", "hip replacement", "major joint surgery", and "random*" for results published through July 2 16 . We did not use any language restrictions. The bibliographies of the obtained publications and the references of relevant reviews were also checked to ensure that no relevant studies were inadvertently omitted.
Data selection and extraction
The literature search and selection were independently performed by two authors, and all disagreements were resolved by discussion. A study was eligible for inclusion if it met the following criteria: 1. it included patients after total hip/knee replacement or arthroplasty or major joint surgery; 2. the patients received thromboprophylactic treatment after joint surgery; 3. the study had a randomized controlled design, and one group was treated with an anticoagulant drug, while another group was treated with a blank, placebo or alternate anticoagulant drug; and 4. one of the following outcomes was included in the study: the number of cases of all-cause VTE, major DVT/PE, all-cause bleeding events, and major bleeding/clinically relevant non-major bleeding events.
The exclusion criteria included the following: 1. the study included another type of surgery; 2. no patients were treated with anticoagulation agents (such as anaesthetics); 3. the study did not include the desired results; 4. the study researched the dose-related effects of only one anticoagulant drug; and 5. the study was a mechanical stress treatment-related controlled trial. Additionally, reviews, conference presentations, letters, basic research articles, and editorials without suf icient data were excluded. Studies that failed to present original data were also eliminated.
We extracted the author, publication year, sample size, age, ratio of males to females, type of surgery, experimental intervention, control intervention, intervention time, subsequent treatment regimens, thrombus diagnosis, and follow-up period. We assessed the methodological quality of the included trials using a risk of bias approach according to the methods described by the Cochrane Collaboration [2 ] .
In our analysis, the major effectiveness outcome was all-cause VTE, and the secondary effectiveness outcome was major DVT or PE. The major tolerance outcome was all-cause bleeding events, and the secondary outcomes were major bleeding/clinically relevant non-major bleeding events. For the ef icacy outcome analysis, we used data from the intention-to-treat population, which comprised randomized patients who received a study agent. Because all the included studies had a randomized controlled trial design, our analysis did not classify the studies as low-risk and high-risk research. Most of the studies recommended or did not limit the application of compression stockings and mechanical extrusion, and we therefore treated mechanical intervention as a blank treatment. We also used the Grading of Recommendation Assessment, Development and Evaluation (GRADE) approach to assess the network meta-analysis quality, with four levels graded from high (best) to very low (worst). This method considered the quality of direct and indirect evidence as well as the quality of network evidence according to the inconsistency between direct and indirect evidence and the intransitivity among all related pieces of evidence. We performed "node splitting" to separate the indirect evidence from the direct evidence to inform these evaluations [21] .
Statistical analysis
We performed a pairwise meta-analysis using a random-effects model. For dichotomous outcomes, odds ratios (ORs) with 5% con idence intervals (CIs) were calculated to determine the sizes of the effects. We also used a random-effects network meta-analysis for mixed multiple treatment comparisons because this approach fully preserves the within-trial randomized treatment comparisons in each trial [22] . Network plots were produced for each outcome, in which nodes are weighted according to the number of studies evaluating each treatment and edges according to the precision of the direct estimate for each pairwise comparison. When a treatment involved more arms, the node was larger, and when the comparison results were more accurate (small standard error), the edges were more weighted. The network analysis adopted a frequentist framework, and a contrast-based model was used to evaluate multi-arm trials. We used a multivariate random-effects meta-regression to pool data with proportional variance-covariance matrix, and a restricted maximum-likelihood method was used to assess model it. Consistency within every closed triangle or quadratic loop was investigated using a loop-speci ic approach to evaluate the coherency between direct and indirect comparisons. During analysis, inconsistency factors (IFs) and their 5% CIs were used to determine their compatibility with zero [23] .
Results

Literature search
In our study, 8 articles were identi ied after duplicates were removed. A total of 757 of these articles were excluded after the titles and abstracts were screened. The full text of the remaining 133 articles was assessed, and the following studies were removed: secondary research studies (8), mechanical treatment-related studies (8) , studies that included other types of surgery (4), studies of anaesthetics and other drugs (3) , studies that evaluated the duration of treatment (2), studies with undesired results (1), duplicate publications (1), studies without a randomized, controlled design (1), and studies that compared preoperative and postoperative drug treatments (1) . Finally, 1 8 treatment comparisons that assessed 11 ,643 patients from 1 4 trials were collected in our systematic review (Fig. 1 
Study characteristics
The age range of the included patients was 3 -8 years. Eight of these studies failed to clearly de ine the ages of the included patients, and three of the studies included patients who were more than 4 years old. In this type of surgery, most of the included studies included patients with knee or hip replacement or arthroplasty, and thirteen trials included patients with major joint surgery, such as hip or knee fracture (Table 1) .
Thirty drugs were included in our analysis. They included vitamin K antagonists (acenocoumarol and warfarin), direct factor Xa inhibitors (apixaban, betrixaban, darexaban, edoxa- ban, rivaroxaban, eribaxaban, and rivaroxaban), a factor XI antisense oligonucleotide (FXI-ASO), a factor VIII inhibitor (TB4 2), direct thrombin inhibitors (dabigatran, melagatran (withdrawn from market), ximelagatran (withdrawn from market), desirudin, and recombinant hirudin), non-steroidal anti-in lammatory agents (aspirin and sudoxicam), heparin and its derivatives (ardeparin (withdrawn from market), certoparin, dalteparin enoxaparin, fondaparinux, unfractionated heparin, logiparin, nadroparin, reviparin, and semuloparin), a platelet aggregation inhibitor (tri lusal), and others (dextran and dihydroergotamine).
als were randomly grouped, and only 2% of trials did not mention the means of random sequence generation. Additionally, 11% of trials did not explicitly mention allocation concealment. Therefore, randomization was completely reliable. In addition, 4% of trials did not explicitly deine the reasons for the loss of participants. However, for application of blinding method, 44% of trials did not set blinding of participants and personnel, and 28% of trials did not set blinding for outcome assessments. Therefore, the most important bias was the in luence of blinding methods on the results and the in luence of subjective assessment bias factors. In the results of these trials, the diagnosis of thrombus was generally based on venography, colour duplex Doppler, or other relatively objective methods if the assessor could be completely concealed; thus, the impact of low assessment blinding quality on the results was small. However, it still was not possible to exclude the in luence of psychological suggestion of the participants and the investigator on the assessor. The judgement of bleeding results is often subjective, particularly if blinding methods are not well designed; therefore, this subjectivity would have a certain impact on the results.
Results of network meta-analysis
In the network meta-analysis, eligible comparisons of all-cause VTE outcomes are presented ( Fig. 2) , which show the predominantly pairwise comparisons of different anticoagulants used for thromboprophylaxis after major joint surgery. Treatments in the network that are not well connected should be interpreted with caution. Moreover, probabilities of which treatment is the best can be fragile when the network is sparse. We removed one study because no other interventions were associated with its interventions. Thus, 1 3 studies and 1 7 comparisons were included for the VTE results (Table 2 ). An inconsistency plot was produced to assume the loop-speci ic heterogeneity estimate; it found 23 triangular loops and 17 quadratic loops. Although there was no signi icant difference between direct and indirect comparisons, we found that there was a relatively large difference between direct and indirection comparisons related to placebo and blank interventions. These inconsistencies may have resulted from differences in the methods used to de ine thrombosis. We therefore used an inconsistency model to research pairwise comparisons, and the forest plot showed that enoxaparin was more advantageous than dextran (logOR, 1.3 ; 5% CI, .74-2. 4; p . 1), and nadroparin was superior to blank treatment (logOR, 1. ; 5% CI, .66-1.52; p . 1). Other results showed no signi icant differences between anticoagulants, and only one study was included in that analysis [Data not shown]. It is notable that it may be improper to include data contained in multiarm studies in a pairwise comparison analysis. Furthermore, we ranked the comparative effects of all anticoagulants in all VTE with SUCRA probabilities (%). The results indicated that rivaroxaban (88.4%), recombinant hirudin (85.6%), and ardeparin (82.7%) were most likely to reduce thrombosis after major joint surgery. These agents were followed by nadroparin (81. %) and TB4 2 (76. %). The comparison-adjusted funnel plot used to assess publication bias and to determine the presence of small-study effects did not suggest that there was any publication bias. However, the global inconsistency analysis showed that there was signi icant inconsistency among the studies (p . 68). Eligible comparisons of major VTE outcomes are presented in Fig. 3 . The exp(IF) of the inconsistency plot that included 1 triangular loops and 3 quadratic loops showed that there was no signi icant difference among the studies. Therefore, we used a consistency model to research pairwise comparisons, and there were no observable low-heterogeneity differences among the comparisons. The comparative effects of all treatments and their SUCRA probabilities revealed that eribaxaban (85. %), rivaroxaban (8 .5%), and warfarin (71. %) were most likely to reduce the risk of major thrombosis after major joint surgery, followed Network of comparisons for all-cause VTE included in the analyses. The nodes are weighted according to the number of studies and edges according to the precision of the direct estimate for each pairwise comparison. API apixaban; ARD ardeparin; ASP aspirin; BET betrixaban; B A blank; CER certoparin; DAB dabigatran; DA dalteparin; DAR darexaban; DES desirudin; DEX dextran; EDO edoxaban; ENO enoxaparin; E N O R e n o x a p a r i n r i v a r o x a b a n ; ERI eribaxaban; FXI FXI-ASO; ON fondaparinux; HEP heparin; HEPA heparin aspirin; HEPD heparin-dihydroergotamine; OG logiparin;ME X m elagatran ximelagatran; NAD nadroparin; P A placebo; RHIR recombinant hirudin; RIV rivaroxaban; SEM semuloparin; SUD sudoxicam; TB4 TB4 2; TRI tri lusal; WAR warfarin; and XIM ximelagatran. The network plot for allcause bleeding outcomes is shown in Fig. 4 Fig. 5 . ENO included the three most frequently researched treatments. The inconsistency plot including four triangular loops and six quadratic loops showed that there Table 2 . The number of arms, events, and patients for each treatment group of each outcome. Abbreviations: VTE: Venous thromboembolism were no signi icant differences among the loops. The consistency model was used to research pairwise comparisons, and there were no observable differences in low heterogeneity among the comparisons. The SUCRA probability scores showed that betrixaban (86. %), dalteparin (74.6%), and warfarin (66.1%) were associated with the lowest risk of major bleeding/non-major clinically relevant bleeding events. Additionally, there was no clear publication bias in the comparison-adjusted funnel plot, and there was no signi icant difference in global inconsistency (p .184). 
OG logiparin; M E X m e l a g a t r a n x i m e l a g a t r a n ; NAD nadroparin; P A placebo; RHIR recombinant hirudin; RIV rivaroxaban; SEM semuloparin; TRI tri lusal; WAR warfarin; and XIM ximelagatran. OG logiparin; M E X m e l a g a t r a n x i m e l a g a t r a n ; NAD nadroparin; P A placebo; RHIR recombinant hirudin; RIV rivaroxaban; SEM semuloparin; SUD sudoxicam; TB4 TB-4 2; TRI tri lusal; WAR warfarin; and XIM ximelagatran. 5 . Network of comparisons for major bleeding/clinically relevant non-major bleeding included in the analyses. API apixaban; ARD ardeparin; ASP aspirin; BET betrixaban; B A blank; DAB dabigatran; DA dalteparin; DAR darexaban; DES desirudin; DEX dextran; EDO edoxaban; ENO enoxaparin; ERI eribaxaban; FON fondaparinux; HEP heparin; ME X melagatran ximelagatran; NAD nadroparin; P A placebo; RIV rivaroxaban; SEM semuloparin; WAR warfarin; and XIM ximelagatran. inhibited major VTE but was associated with a high risk of major/clinically relevant nonmajor bleeding events (Fig. 7) .
Quality of evidence and sensitivity analysis
We simpli ied the results of all the comparisons in the GRADE assessment and only listed treatments related to the inal conclusion and its direct comparisons (Table 3) . For all-VTE outcomes, apixaban had ive direct comparisons with moderate and high quality. Although the quality level of aspirin in the network comparisons was generally low, the seventeen related direct comparisons increased the robustness of the results. Ardeparin had only two comparisons with moderate and low levels, and FXI-ASO had only one lowquality comparison. Thus, the results of these two treatments lacked robustness. In addition, there was incoherence between the direct and indirect comparisons of apixaban versus enoxaparin, ardeparin versus blank, ardeparin versus placebo, and aspirin versus placebo. For the all-cause bleeding outcome, apixaban had ive direct comparisons with a high level of quality, and aspirin had ten direct comparisons with a generally moderate level. The results of ardeparin and FXI-ASO still lacked robustness.
For the major VTE outcome, warfarin had six direct comparisons with moderate and low quality; betrixaban, dalteparin, and eribaxaban all included only one direct comparison without robustness. For the major bleeding outcome, dalteparin had seven comparisons with a moderate-high level of quality; warfarin had four comparisons of a low-moderate level of quality. The results of betrixaban and eribaxaban were still not robust because of fewer comparisons. Additionally, for major VTE and bleeding outcomes, most included trials contained small sample sizes and zero-event results, which reduced the quality of evidence because of imprecision. In the sensitivity analysis, we removed the relatively low-design-quality trials. For the all-cause VTE outcome, fondaparinux (SUCRA: 67% to 3. %), rivaroxaban (SUCRA: 88.4% to 3%), edoxaban (SUCRA: 6 . % to 2.8%) were generally best. In conclusion-relative treatment, apixaban (SUCRA: 66.7%-82.8%) was still ideal, while aspirin (SUCRA: 52.8% to 26.1%), ardeparin (SUCRA: 82.7% to 23.2%), and FXI-ASO (miss) were less dominant. For the all-cause bleeding outcome, betrixaban (SUCRA: 88.3% to .5%), aspirin (SUCRA: 73.6% to 82.7%), and warfarin (SUCRA: 6 .2% to 78. %) were best. In key treatment, apixaban (SUCRA: 62.7% to 62.2%), aspirin (SUCRA: 73.6% to 82.7%), and ardeparin (SUCRA: 65.4% to 56.6%) were best. Combined with the GRADE results, apixaban and aspirin were relatively robust. Further, when only considering well-designed trials, the result of apixaban was more robust. 73 .5%), and warfarin (SUCRA: 71. % to 7 .8%) were generally best after removing low-quality studies. In key treatment, only warfarin had ideal results; other treatments were missing. For the major bleeding outcome, dalteparin (SUCRA: 74.6% to 81.6%), warfarin (SUCRA: 66.1% to 76.7%), and semuloparin (SUCRA: 65.8% to 72.7%) were the best treatments. In conclusion-related treatment, dalteparin, warfarin, and betrixaban (SUCRA: 86. % to 56.8%) were still ideal; the result of eribaxaban was missing. Thus, in terms of secondary outcomes, warfarin had a robust effect, and apixaban still showed advantages in inhibiting major VTE and bleeding.
Discussion
In this study, we performed a network meta-analysis to analyse VTE and bleeding events in patients who underwent major joint surgery and were subsequently treated with thromboprophylactics. We included several types of anticoagulant in the analysis, including vitamin K antagonists, direct factor Xa inhibitors, factor XI antisense oligonucleotides, factor VIII inhibitors, direct thrombin inhibitors, non-steroidal anti-in lammatory agents, heparin and its derivatives, and platelet aggregation inhibitors. The results showed that FXI-ASO, ardeparin, aspirin, and apixaban were ideal for preventing all-cause VTE and reducing all bleeding events, while betrixaban, dalteparin, warfarin, and eribaxaban were ideal for preventing major VTE and reducing major/clinically relevant non-major bleeding events.
All-cause VTE events that have been described in clinical records typically include asymptomatic DVT, objective symptomatic VTE, and fatal PE, and the diagnostic methods used to evaluate these conditions have included venography (phlebography), ultrasonography, and an objective review of records [136] . The bleeding events that occur after anticoagulant treatment typically include clinically relevant bleeding (major or clinically non-major bleeding) and minor bleeding. Major bleeding was de ined as a decrease in haemoglobin of 2 g per decilitre or necessitating transfusion of 2 or more units of blood [137] , and clinically relevant non-major bleeding included non-major bleeding that required intervention or consultation with a physician and had clinical consequences [2 ] . Minor bleeding included haemorrhagic wound complications or other bleeding-related adverse events [138] . However, there may be slight differences among the assessors for VTE and bleeding judgement, especially in non-major events.
The loop-speci ic inconsistency analysis and GRADE assessment revealed some differences between direct and indirect comparisons. The cause of these inconsistencies may include differences in adjuvant therapy or physiotherapy, especially in blank and placebo intervention arms. In these empty intervention arms, other adjuvant therapy would be used to prevent thrombosis. The decision whether to undergo physiotherapy was due to the daily activity of patients. In addition, the zero-event trials may have made the direct and indirect comparisons less robust. In the comprehensive analysis, the effectiveness of apixaban was ideal and robust. Apixaban is a direct inhibitor of factor Xa that can directly combine with factor Xa to prevent coagulation cascades and is therefore widely applied in the clinical setting [13 ] . This mechanism of this anticoagulant may play a signi icant role in thromboprophylaxis after major joint surgery.
The sensitivity analysis revealed that aspirin was not ideal in preventing thrombosis, but it still had high tolerability to inhibit bleeding. We also found that ive of twenty-ive patients developed VTE in an arm that combined the use of heparin and aspirin and even applied compression treatment at the same time [111] . This inding sugests the combination of heparin and aspirin has negative synergistic effects for thromboprophylaxis.
In the global inconsistency assessment, we found the all-VTE outcome had complete inconsistency. It was notable that improvements in surgical technology and perioperative nursing could reduce thrombosis and bleeding events. Therefore, in theory, if more of these trials are conducted, a smaller number of patients should experience thrombosis and bleeding.
Major VTE was usually considered as a secondary outcome in the included studies. These cases included proximal DVT, non-fatal PE or deaths associated with VTE during follow-up. However, major bleeding events were usually treated as a major safety outcome in these studies. Our results indicated that betrixaban, dalteparin, apixaban, warfarin, and eribaxaban were ideal for preventing major VTE and reducing the risk of major bleeding. Rivaroxaban was effective at preventing thrombosis but was more likely to cause major bleeding events. It is interesting that betrixaban and eribaxaban, which are direct factor Xa inhibitors, were not ideal for preventing all-cause thrombosis or bleeding but provided advantages when treating major thrombosis and bleeding events. These drugs were potent, orally active and highly selective for factor Xa, and they were selected from a group of similar compounds because of their low af inity for the human ether--go-go-related gene (hERG) and showed favourable effectiveness for preventing PE in particular [14 ] . The U.S. Food and Drug Administration has granted a Fast Track designation to betrixaban for the extendedduration prevention of VTE in acutely ill patients. In this study, dalteparin and warfarin, a heparin derivative and vitamin K antagonist, respectively, were ideal for inhibiting major thrombosis and bleeding events. The effect of rivaroxaban was similar to the above all-cause results, which showed that this drug was effective at preventing major thrombosis but was associated with a high risk of major bleeding events.
Research aimed at preventing thrombosis after joint surgery is generally focused on the use of various types of anticoagulants. Therefore, a network meta-analysis could help us to obtain a more comprehensive understanding of the effectiveness of these drugs and patient tolerability in addition to allowing us to perform indirect comparisons. A previous network meta-analysis of direct factor X inhibitors described results that were similar to ours with regard for the ranking of drugs according to total VTE risk. These rankings were as follows, from high to low: rivaroxaban, apixaban, edoxaban, enoxaparin, darexaban, and betrixaban. The rankings for the ability to reduce major and clinically relevant non-major bleeding were as follows, from low to high: betrixaban, enoxaparin, darexaban, edoxaban, apixaban, and rivaroxaban. Our research also included other types of anticoagulants in addition to direct factor X inhibitors, such as factor XI antisense oligonucleotides, factor VIII inhibitors, direct thrombin inhibitors, non-steroidal anti-in lammatory agents and vitamin K antagonists. We comprehensively analysed all-cause thrombosis/bleeding events and major thrombosis/ bleeding events to provide a valuable reference for clinical applications. However, as some anticoagulants included in our work are under development, those indings are of limited value for clinicians. Most importantly, surgical techniques and perioperative nursing have greatly evolved from the time of the irst studies included in our work until now, such that the impact of such improvements on bleeding events and possibly on VTE events is potentially important.
There are several limitations to our study. First, our analysis was performed at the study level but not at the individual level. Second, there is unexplained heterogeneity in our analysis. This may result from differences in daily drug doses, application times, mechanical treatment effects, follow-up times, or thrombosis/bleeding event-related criteria because this ield has gradually matured in recent years. Third, our study did not evaluate the use of haemoglobin, blood transfusion amounts, or blood drainage as assessment indexes in the analysis of results.
Conclusion
In conclusion, our study indicates that FXI-ASO, ardeparin, aspirin, and apixaban are ideal for preventing all-cause VTE and reducing all bleeding events, among which apixaban is the most reliable. Betrixaban, dalteparin, warfarin, and eribaxaban are ideal for preventing major VTE and reducing major/clinically relevant non-major bleeding events, among which Fuji T, Fujita S, Kawai Y, Nakamura M, Kimura T, Fukuzawa M, Abe K, Tachibana S: Ef icacy and safety of edoxaban versus enoxaparin for the prevention of venous thromboembolism following total hip arthroplasty: STARS J-V. Thromb J 2 15;13:27. 32
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